CSO Bill Lundberg transitions to advisor role at CRISPR Therapeutics; Prothena loses CMO Sarah Noonberg; Sanofi vet Mark Nuttall jumps to Kymera
→ Wrapping a three-year run marked by the first clinical trial applications for CRISPR-based therapies, Bill Lundberg is stepping down as CSO of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
